Anika (Nikki) Johal的动态

???Exploring Membrane Proteins in Drug Discovery??? Did you know that 60% of drug targets are membrane proteins? Despite their importance, they can be quite challenging to study. In our latest application note, we delve into how the SELECT SERIES Cyclic IMS instrument is lending a hand in this field by providing high-quality native MS data for membrane proteins. Read the application note here - https://lnkd.in/eqBKeUsA Key Highlights: - Efficient Micelle Removal:?The instrument’s declustering capabilities ensure high-quality spectral data for membrane proteins. - CCS Measurement:?Cyclic ion mobility enables CCS measurement, allowing us to track crucial structural changes. - Enhances Drug Discovery Workflows:?Enabling the detection and identification of candidate therapeutics. Returning to my native MS roots, I had the pleasure of collaborating with the talented team at OMass Therapeutics – Feng Qu, Kleitos Sokratous, Idlir Liko and Jonathan Hopper – to showcase the SELECT SERIES Cyclic IMS for these challenging analytes. #Teammassspec #pharma #membraneproteins #nativems #drugdiscovery

In Part 1 of his #BusinessofBiotech interview, with Matthew Pillar and Anna Rose Welch, Tal Zaks, chairman and CEO of Exsilio Therapeutics, discusses the critical role of innovation and intellectual property in the biotech ecosystem. He highlights that while unmet medical needs guide the focus of therapeutic development, the source of true innovation comes from scientific curiosity and technological breakthroughs. He uses the development of lipid nanoparticles as an example of how a foundational scientific discovery can lead to impactful therapies. Dr. Zaks also discusses how return on investment is vital for supporting high-risk innovation, as well as the value of generic medicines and their role in making therapeutics widely available. This thought-provoking discussion sheds light on the drivers of the biotech industry. Watch on YouTube: https://lnkd.in/gZU7CRpg Or watch online: https://lnkd.in/gZaPgP7N #Biotech?#BioPharma #Innovation #IntellectualProperty #ScientificDiscovery?

Navigating the complexities of cell-based bioassays (CBBAs) is key to driving success in the development of advanced therapeutics. In this webinar, Jung-Hua YEH, PhD, Principal Scientist, and Reginald Clayton, PhD, Head of Biosafety and Deputy Site Head, will delve into: ? Method selection for different modalities, with a focus on potency ? Key considerations and common pitfalls in assay development ? A case study on potency assays for antibody-drug conjugates ? The importance of a two-way partnership to ensure efficiency and program success Don't miss this opportunity to learn from industry experts and keep your drug development programs on track. ?? Register now: https://lnkd.in/eyM9dFZe #cbba #cellbasedbioassays #bioassays #drugdevelopment #celltherapies #genetherapies #atmps

SFBN Feed: Sutro Biopharma and Boehringer Ingelheim BioXcellence? collaboration: Established first-in-class cell-free capabilities at commercial scale https://lnkd.in/g3qkhpca SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) — Boehringer Ingelheim BioXcellence? and Sutro Biopharma Inc.?today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture luveltamab tazevibulin?(luvelta), [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

?? Exciting September Ahead for CPC Scientific! ?? We’re thrilled to announce that CPC Scientific, a leading manufacturer of oligonucleotides and peptides, will be showcasing our expertise and solutions at several major industry events this September: ?? RNA Leaders (Sept 4-5) ?? ChemOutsourcing (Sept 3-6) ?? Oligonucleotide Therapeutics and Delivery (Sept 9-10) ?? Boulder Peptide Symposium (Sept 16-19) As a trusted partner in oligonucleotide and peptide manufacturing, we look forward to connecting with industry peers, sharing our latest advancements, and exploring new collaborations. Whether you're interested in our advanced oligonucleotide synthesis or innovative peptide solutions, we invite you to visit our booths and meet with our business development team members to discover how CPC Scientific can support your next project. Stay tuned for more details on our participation and how to engage with us. We look forward to seeing you at these exciting events! #CPCScientific #OligonucleotideManufacturing #PeptideManufacturing #ChemOutsourcing #OligonucleotideTherapeutics #RNALeaders #BoulderPeptideSymposium #Biotech #Pharma #Innovation #Networking #TradeShows

?? We’ll be at TIDES in Hamburg next week! Join us from November 11-14 as Luísa Aguiar presents her poster, "Greener Synthesis and Purification Solutions in the New Era of Peptide Therapeutics." ?? This is a fantastic opportunity to delve into sustainable advancements in peptide development and discuss the trends shaping the future of the field. Let’s connect at booth #316! Our experts, Cátia Teixeira and Luísa Aguiar, look forward to sharing how our PurePep solutions can take your peptide projects to the next level. ?? The peptide therapeutics landscape is rapidly evolving, driven by two major trends: ? Innovative Screening Platforms: Chemical and display screening platforms are becoming the new standard for target-based drug development, enriching the preclinical pipeline significantly. ? GLP-1 Analogs Success: The breakthrough in GLP-1 analogs for weight loss and obesity is transforming pharmaceutical interest in peptides, leading to high demand and a capacity crunch in synthesis. We’re here to help you navigate these changes—see you in Hamburg! #purepep #forpeptidescientists #synthesis #purification

SFBN Feed: Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases https://lnkd.in/guiX4UPT FOSTER CITY, Calif. & BALLERUP, Denmark–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Base Editing Market Worth $549 Million Download a PDF Brochure: https://lnkd.in/dr_-m3Nq ?????? ?????????????????? ???????????????? ???? ???????? ???????????? ??????????????: Danaher Corporation, Merck KGaA, Darmstadt, Germany, Revvity, Maravai LifeSciences, GenScript, Beam Therapeutics, Intellia Therapeutics, Inc., Cellectis, ElevateBio, Creative Biogene, Bio Palette Co., Ltd., Addgene, Synthego Corporation, EdiGene Inc., Shape TX (US), Pairwise , ProQR Therapeutics, QI- Biodesign (China), KromaTiD? Inc., and GenKOre. (South Korea) Other Companies that are Operating in this Market Globally: Beam Therapeutics Mammoth Biosciences Rapport Therapeutics MOMA Therapeutics LifeMine Therapeutics Dewpoint Therapeutics Valo Health Arrakis Therapeutics Simulations Plus, Inc. Covaris Skyhawk Therapeutics OpenEye, Cadence Molecular Sciences Jnana Therapeutics Enanta Pharmaceuticals NGM Biopharmaceuticals Quantori Biocytogen Iambic Therapeutics MDS Pharma Services NanoCellect Biomedical, Inc. X-Chem, Inc. XtalPi Inc. Bolt Biotherapeutics, Inc. #BaseEditing #GeneEditing #CRISPR #HealthTech #Biotechnology #MedicalResearch #Genomics #LifeSciences #HealthcareInnovation #DNAEditing #PrecisionMedicine #BiomedicalResearch #MolecularBiology #ClinicalResearch #ScientificResearch #GeneticEngineering #HealthcareTechnology #Biotech #GeneticResearch #MarketResearch

We’re pleased to announce that the Bacteriophage Therapy Summit will return to Boston in March 2025! Back for its 7th year, this meeting will address all your burning questions and challenges from regulatory investment to developing personalized off-the-shelf therapies to fight AMR in infectious diseases! This year we have an expert speaker lineup including experts from PHIOGEN, Biomedical Advanced Research and Development Authority (BARDA), Armata Pharmaceuticals, Inc., Kinzbio, PhagePro, Locus Biosciences, Inc. and more who will share clinical data, explore investment opportunities for bacteriophage companies, and tackle the regulatory challenges in development. Curious to learn more? Explore phage opportunities at our summit here: https://ter.li/yy6ten #bactiophage #phage #AMR #bacteriophageconference?

Very excited that we've now launched the agenda for the 2025 DNA Process Development Summit, returning for the second time to Boston in March. Covering DNA production through optimizing process development and streamlining IND approval, we're excited to bring key biopharma leaders together. Particularly excited for discussions around Cell-Free (or Synthetic) DNA vs Plasmid production to optimize this process, with a dedicated workshop from Pfizer and Beam Therapeutics on Day 2. Our key partners are helping us bring this together and also sharing their insights: Aldevron - Sartorius - ELEGEN - Syngoi Technologies - SGS Does your organisation support DNA production (synthetic or plasmid), provide enzymes for DNA synthesis, or provide solutions / equipment for DNA purification ? Get in touch and we can connect on how we can help your commercial objectives. Full agenda: https://ter.li/cei1pd #DNA #mRNA #Celltherapy #Genetherapy #Plasmids #PlasmidDNA #DNASynthesis #SyntheticDNA